Differentiating osteoradionecrosis from nasopharyngeal carcinoma tumour recurrence using ⁹⁹Tcm-sestamibi SPECT/CT
1Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore. andrew.tan@singhealth.com.sg
The British Journal of Radiology
|August 19, 2011
Summary
Osteoradionecrosis (ORN) of the skull base is a radiotherapy complication. Technetium-99m-sestamibi SPECT/CT effectively differentiated ORN from tumor recurrence when other imaging was inconclusive.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiotherapy
Background:
- Osteoradionecrosis (ORN) of the skull base is a serious complication following radiotherapy for nasopharyngeal carcinoma.
- It is often attributed to radiation-induced endarteritis, leading to tissue damage and fibrosis.
- Distinguishing ORN from tumor recurrence is clinically critical but challenging.
Observation:
- This case report details the use of technetium-99m-sestamibi SPECT/CT.
- Previous imaging modalities, including bone scintigraphy and fluorodeoxyglucose PET/CT, provided equivocal results.
- SPECT/CT was employed to differentiate between osteoradionecrosis and tumor recurrence.
Findings:
- Technetium-99m-sestamibi SPECT/CT successfully differentiated osteoradionecrosis from tumor recurrence.
- This imaging technique proved valuable when other methods were inconclusive.
Implications:
- Accurate differentiation of ORN from tumor recurrence is crucial for appropriate patient management.
- Technetium-99m-sestamibi SPECT/CT offers a potential solution for ambiguous cases.
- This case highlights the utility of advanced nuclear imaging in managing radiotherapy complications.
